Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study

被引：10

作者：

Konishi, Sakae ^{[1
]}

Hatakeyama, Shingo ^{[1
]}

Numakura, Kazuyuki ^{[2
]}

Narita, Shintaro ^{[2
]}

Inoue, Takamitsu ^{[2
]}

Saito, Mitsuru ^{[2
]}

Tokui, Noriko ^{[1
]}

Yamamoto, Hayato ^{[1
]}

Yoneyama, Takahiro ^{[1
]}

Hashimoto, Yasuhiro ^{[1
]}

Yoshikawa, Kazuaki ^{[3
]}

Narita, Satoshi ^{[4
]}

Kawaguchi, Toshiaki ^{[5
]}

Habuchi, Tomonori ^{[2
]}

Ohyama, Chikara ^{[1
]}

机构：

[1] Hirosaki Univ, Dept Urol, Grad Sch Med, 5 Zaifu Chou, Hirosaki, Aomori 0368562, Japan

[2] Akita Univ, Dept Urol, Grad Sch Med, Akita, Japan

[3] Mutsu Gen Hosp, Dept Urol, Mutsu, Aomori, Japan

[4] Odate Municipal Gen Hosp, Dept Urol, Odate, Japan

[5] Aomori Prefectural Cent Hosp, Dept Urol, Aomori, Japan

来源：

CLINICAL GENITOURINARY CANCER | 2019年 / 17卷 / 05期

基金：

日本学术振兴会;

关键词：

Heterogeneity; Metastasis; Prognostic model; Renal-cell carcinoma; Risk criteria; THERAPY; EXPERIENCE; SORAFENIB; SURVIVAL;

D O I：

10.1016/j.clgc.2019.07.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We validated the characteristics of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model in patients with metastatic renal-cell carcinoma treated with axitinib in the first-line setting. The IMDC prognostic model was active in patients who received axitinib in the first-line setting. The combination of C-reactive protein value with the number of positive risk factors might predict prognosis in patients in the IMDC intermediate-risk group. Background: The objective of the study was to validate the characteristics of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model in patients treated with first-line axitinib in clinical practice. Patients and Methods: We retrospectively evaluated 143 patients with metastatic renal-cell carcinoma who were treated with axitinib as the first-line therapy between October 2008 and February 2019. Overall survival (OS) was evaluated according to the IMDC prognostic model. We investigated the intragroup heterogeneity in the intermediate-risk group and divided these patients according to abnormal C-reactive protein (CRP) levels. An inverse probability of treatment-weighted (IPTW)-adjusted Cox regression analysis was performed to evaluate the effects of the CRP-risk model of OS in the patients in the IMDC intermediate-risk group. Results: A significant difference in OS was observed in patients in the IMDC intermediate- and poor-risk group, although no significant difference was observed between the IMDC favorable- and intermediate-risk group. Significantly shorter prognosis was observed in patients in the IMDC intermediate-risk group who had 2 risk factors and CRP >= 0.3 mg/dL (inter-high group) than in those with 1 risk factor or 2 risk factors with CRP <0.3 mg/dL (inter-low group). IPTW-adjusted Cox regression analysis revealed significant differences in the OS between the inter-low and inter-high groups. Conclusion: The IMDC prognostic model was active in patients who received first-line axitinib treatment. The combination of CRP value with the number of positive risk factors in the IMDC model might predict prognosis in patients with IMDC intermediate-risk treated with first-line axitinib.

引用

页码：E1080 / E1089

页数：10

共 37 条

[1] Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan [J].

Harada, Kenichi ;

Nozawa, Masahiro ;

Uemura, Motohide ;

Tatsugami, Katsunori ;

Osawa, Takahiro ;

Yamana, Kazutoshi ;

Kimura, Go ;

Fujisawa, Masato ;

Nonomura, Norio ;

Eto, Masatoshi ;

Shinohara, Nobuo ;

Tomita, Yoshihiko ;

Kondo, Yukihiro ;

Ochi, Kenya ;

Anazawa, Yoshio ;

Uemura, Hirotsugu .

INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 (02) :202-210

[2] Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study [J].

Heng, Daniel Y. C. ;

Xie, Wanling ;

Regan, Meredith M. ;

Warren, Mark A. ;

Golshayan, Ali Reza ;

Sahi, Chakshu ;

Eigl, Bernhard J. ;

Ruether, J. Dean ;

Cheng, Tina ;

North, Scott ;

Venner, Peter ;

Knox, Jennifer J. ;

Chi, Kim N. ;

Kollmannsberger, Christian ;

McDermott, David F. ;

Oh, William K. ;

Atkins, Michael B. ;

Bukowski, Ronald M. ;

Rini, Brian I. ;

Choueiri, Toni K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5794-5799

[3] Impact of bacillus Calmette-Guerin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy [J].

Horiguchi, Hirotaka ;

Yoneyama, Takahiro ;

Hatakeyama, Shingo ;

Tokui, Noriko ;

Sato, Tendo ;

Fujita, Naoki ;

Yamamoto, Hayato ;

Tobisawa, Yuki ;

Yoneyama, Tohru ;

Hashimoto, Yasuhiro ;

Koie, Takuya ;

Yoshikawa, Kazuaki ;

Narita, Satoshi ;

Kawaguchi, Toshiaki ;

Ohyama, Chikara .

MEDICAL ONCOLOGY, 2018, 35 (04)

[4] Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma [J].

Hosogoe, Shogo ;

Hatakeyama, Shingo ;

Kusaka, Ayumu ;

Hamano, Itsuto ;

Iwamura, Hiromichi ;

Fujita, Naoki ;

Yamamoto, Hayato ;

Tobisawa, Yuki ;

Yoneyama, Tohru ;

Yoneyama, Takahiro ;

Hashimoto, Yasuhiro ;

Koie, Takuya ;

Ohyama, Chikara .

EUROPEAN UROLOGY FOCUS, 2018, 4 (06) :946-953

[5] Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial [J].

Hutson, Thomas E. ;

Al-Shukri, Salman ;

Stus, Viktor P. ;

Lipatov, Oleg N. ;

Shparyk, Yaroslav ;

Bair, Angel H. ;

Rosbrook, Brad ;

Andrews, Glen I. ;

Vogelzang, Nicholas J. .

CLINICAL GENITOURINARY CANCER, 2017, 15 (01) :72-76

[6] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial [J].

Hutson, Thomas E. ;

Lesovoy, Vladimir ;

Al-Shukri, Salman ;

Stus, Viktor P. ;

Lipatov, Oleg N. ;

Bair, Angel H. ;

Rosbrook, Brad ;

Chen, Connie ;

Kim, Sinil ;

Vogelzang, Nicholas J. .

LANCET ONCOLOGY, 2013, 14 (13) :1287-1294

[7] Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas [J].

Ito, Keiichi .

INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 (09) :868-877

[8] Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma [J].

Kang, Minyong ;

Yu, Jiwoong ;

Sung, Hyun Hwan ;

Jeon, Hwang Gyun ;

Jeong, Byong Chang ;

Park, Se Hoon ;

Jeon, Seong Soo ;

Lee, Hyun Moo ;

Choi, Han Yong ;

Seo, Seong Il .

INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 (06) :596-603

[9] Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma [J].

Karam, Jose A. ;

Devine, Catherine E. ;

Urbauer, Diana L. ;

Lozano, Marisa ;

Maity, Tapati ;

Ahrar, Kamran ;

Tamboli, Pheroze ;

Tannir, Nizar M. ;

Wood, Christopher G. .

EUROPEAN UROLOGY, 2014, 66 (05) :874-880

[10] Oncologic outcomes for open and laparoscopic radical nephroureterectomy in patients with upper tract urothelial carcinoma [J].

Kido, Koichi ;

Hatakeyama, Shingo ;

Fujita, Naoki ;

Yamamoto, Hayato ;

Tobisawa, Yuki ;

Yoneyama, Tohru ;

Yoneyama, Takahiro ;

Hashimoto, Yasuhiro ;

Koie, Takuya ;

Iwabuchi, Ikuya ;

Ogasawara, Masaru ;

Kawaguchi, Toshiaki ;

Ohyama, Chikara .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (04) :726-733

← 1 2 3 4 →